Indian trademark rights, brand for anti-diabetic drug Vildagliptin acquired by Cipla

Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.

New Delhi: Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn't disclose the acquisition amount.

Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.

"Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said.

Read Also: Cipla associate Avenue Therapeutics files US application for IV tramadol

The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said.

Vildagliptin is backed by strong clinical data and is, therefore, a widely prescribed antidiabetic medicine for adults with type-2 diabetes mellitus, it added

The market size of Vildagliptin in India is Rs 818 crore as per IQVIA MAT data of November 2019, Cipla said.

Read Also: Cipla shares jump 2 pc post agreement with CitiHealth Imports